In this regard, hexokinase 2 (HK2), a rate-limiting glycolytic enzyme that turns on the metabolic switch for cancer progression and vascularization, can be activated by a variety of proangiogenic molecules, including hypoxia-inducible factor-1α (HIF1A), vascular endothelial growth factor (VEGFA) and some members of the fibroblast growth factor (FGF) family [15,16]. This evidence concerns the gene VEGFA and cancer.